Leucine Rich Bio, a genomics and biotechnology company, has launched the BugSpeaks Vaginal Microbiome Test to expand its diagnostic portfolio into women’s reproductive and urogenital health. The company describes the test as the first of its kind available across South and Middle East Asia, marking a new development in microbiome-based women’s healthcare. The launch builds on the company’s existing BugSpeaks Gut Microbiome Test and Facial Skin Microbiome Test. With this addition, Leucine Rich Bio aims to extend its precision multi-omics capabilities to an area of healthcare where conventional diagnostic methods may not fully capture the complexity of microbial communities.
Vaginal Microbiome Testing Aims to Identify Early Health Risks
Traditional methods, including microbial culture tests, have limitations in detecting the full range of microorganisms and their interactions within the vaginal environment. The BugSpeaks Vaginal Microbiome Test uses a broader approach to assess the local microbial ecosystem and identify patterns associated with potential health concerns. According to the company, the test aims to identify early signs of vaginal dysbiosis, assess risks associated with reproductive health and fertility, and provide insights into menopausal transitions and intimate discomfort. These findings are intended to support personalised health recommendations and proactive healthcare planning.
Whole Metagenome Sequencing Powers the Diagnostic Test
The test uses Whole Metagenome Shotgun Sequencing technology from Oxford Nanopore Technologies. It processes the resulting data through Leucine Rich Bio’s proprietary MetaRich bioinformatics pipeline, MicroByte database and NutriByte nutritional intelligence framework.
The diagnostic report covers eight key areas:
Vaginal dysbiosis and infections
Reproductive health and fertility
Susceptibility to sexually transmitted infections (STIs)
Menopausal transitions
Microbial composition and predicted vaginal pH
Functional secretions
The gut-vagina axis
Antimicrobial resistance profiling
Together, these areas provide insights into vaginal microbial composition and its potential relationship with different aspects of reproductive and urogenital health.
Personalised Recommendations Support Individualised Care
Beyond microbial analysis, the test translates its findings into personalised recommendations. These include dietary suggestions featuring prebiotic and polyphenol-rich foods, along with proposed topical and oral probiotic strains tailored to individual test results. However, such recommendations should be interpreted in consultation with qualified healthcare professionals. Microbiome findings alone do not establish a clinical diagnosis, and the effectiveness of specific dietary or probiotic interventions may vary depending on the individual and the condition being assessed.
Company Highlights a Shift Towards Preventive Women’s Healthcare
Dr Debojyoti Dhar, Co-Founder and Director of Business Development and Innovation at Leucine Rich Bio, said the test combines whole metagenome sequencing with proprietary analytical algorithms to provide insights into vaginal dysbiosis, fertility, menopausal changes and antimicrobial resistance. He emphasised the importance of moving beyond symptom-based treatment towards a more comprehensive understanding of microbial ecosystems and their potential role in health. Kumar Sankaran, Founder and CEO of Leucine Rich Bio, described the launch as an important milestone in expanding the BugSpeaks product portfolio. He noted that the test aims to give healthcare providers and patients molecular-level insights into urogenital health and support more individualised approaches to long-term wellness.
Quality Standards Underpin Test Development
Leucine Rich Bio states that the test was developed using quality processes certified to ISO 9001:2015 and ISO/IEC 17025:2017 standards. With the launch of the BugSpeaks Vaginal Microbiome Test, the company aims to broaden access to microbiome-based insights in women’s healthcare across South and Middle East Asia. As per the press release, the test represents an emerging approach to understanding microbial health, although its clinical utility and recommendations should be evaluated in the context of established medical evidence and individual patient needs.